Stem Cell Team Grows Heart Valve
Opponents of stem cell research might want to reconsider their position if any of their nearest and dearest have ever had heart problems. A team of British scientists has successfully grown a human heart valve from stem cells, an astonishing feat 10 years in the making.Opponents of stem cell research might want to reconsider their position if any of their nearest and dearest have ever had heart problems. A team of British scientists has successfully grown a human heart valve from stem cells, an astonishing feat 10 years in the making.
Rock Solid JournalismBBC:
Heart surgeon Sir Magdi Yacoub, who led the team, said doctors could be using artificially grown heart components in transplants within three years.
His researchers at Harefield hospital managed to grow tissue that works in the same way as human heart valves.
Sir Magdi told the Guardian newspaper a whole heart could be produced from stem cells within 10 years.
In 2026, amid chaos and the nonstop flurry of headlines, Truthdig remains independent, fact-based and focused on exposing what power tries to hide.
Support Independent Journalism.
Researchers in the U.K. have found a way to make the hearts of mice repair themselves -- a feat that the British Heart Foundation calls the "holy grail" (when applied to humans, we're guessing). (more)
Energy drinks might have more serious side effects for children and teenagers than just getting them good and hyper, according to a group of doctors who released a cautionary report in the journal Pediatrics, warning that the amped-up beverages might trigger seizures and other highly undesirable reactions in rare cases. As it happens, they should also lay off the Gatorade.
Advertisers make all kinds of claims about the magical qualities of their clients' products, but in the case of POM -- the supposedly "wonderful" pomegranate juice in that shapely bulbous bottle -- the fruity company might have crossed the line, according to the FTC.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.